XCUR

Exicure, Inc. · NASDAQ

Performance

+6.69%

1W

+220.79%

1M

+375.06%

3M

+1031.52%

6M

+543.46%

YTD

+500.32%

1Y

Profile

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Technical Analysis of XCUR 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Oscillators Score of 60 suggests a neutral but potentially positive trend. Overall, the combined Technical Score of 71 reinforces a favorable outlook for the stock, signaling continued strength in the market.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of XCUR

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.